AR088969A1 - Derivados de pirrolidina - Google Patents

Derivados de pirrolidina

Info

Publication number
AR088969A1
AR088969A1 ARP120104409A ARP120104409A AR088969A1 AR 088969 A1 AR088969 A1 AR 088969A1 AR P120104409 A ARP120104409 A AR P120104409A AR P120104409 A ARP120104409 A AR P120104409A AR 088969 A1 AR088969 A1 AR 088969A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
haloalkyl
alkoxy
Prior art date
Application number
ARP120104409A
Other languages
English (en)
Inventor
Banner David
Haap Wolfgang
Kuhn Bernd
Luebbers Thomas
Peters Jens
Uwe-Schulz-Gasch Tanja
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR088969A1 publication Critical patent/AR088969A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) en la que: A es carbonilo o está ausente; R¹ es alcoxi, nitrofenilo, 1H-pirazolilo sustituido por alquilo y cicloalquilo, alquilcicloalquilo, haloalquilcicloalquilo, fenilcicloalquilo, halofenilcicloalquilo, piridinilcicloalquilo o halopiridinilcicloalquilo; R² y R³ se eligen con independencia entre hidrógeno, alquilo y cicloalquilalquilo; o R² y R³ junto con el átomo de carbono, al que están unidos, forman un cicloalquilo; R⁴ es -C(O)NR⁸R⁹ o benzooxazolilo; R⁵, R⁶ y R⁷ se eligen con independencia entre hidrógeno, alquilo, halógeno, haloalquilo, alcoxi, haloalcoxi y morfolinilo; y uno de R⁸ y R⁹ es hidrógeno o alquilo y el otro es alquilo, alcoxialquilo, cicloalquilo, haloalquilo, fenilalquilo, naftilalquilo o tetrahidropiranilo; o una sal o un éster farmacéuticamente aceptable del mismo.
ARP120104409A 2011-11-25 2012-11-23 Derivados de pirrolidina AR088969A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11190756 2011-11-25

Publications (1)

Publication Number Publication Date
AR088969A1 true AR088969A1 (es) 2014-07-23

Family

ID=47216270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104409A AR088969A1 (es) 2011-11-25 2012-11-23 Derivados de pirrolidina

Country Status (11)

Country Link
US (1) US8729061B2 (es)
EP (1) EP2782903B1 (es)
JP (1) JP2014533707A (es)
KR (1) KR20140102253A (es)
CN (1) CN103946213A (es)
AR (1) AR088969A1 (es)
BR (1) BR112014012521A2 (es)
CA (1) CA2854569A1 (es)
MX (1) MX2014006211A (es)
RU (1) RU2014123784A (es)
WO (1) WO2013076063A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227282B1 (en) 2014-12-02 2019-04-03 F.Hoffmann-La Roche Ag Novel piperidine derivatives
LT3419970T (lt) * 2016-02-26 2020-03-10 F. Hoffmann-La Roche Ag Nauji pirolidino dariniai
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
WO2023130334A1 (zh) * 2022-01-07 2023-07-13 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2651043A1 (en) * 2006-05-23 2007-12-06 David C. Tully Compounds and compositions as channel activating protease inhibitors
JP2009538327A (ja) * 2006-05-23 2009-11-05 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤である化合物および組成物
EA016327B1 (ru) * 2007-02-09 2012-04-30 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
MX2009008493A (es) * 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
EP2237793A4 (en) * 2008-02-07 2013-07-31 Virobay Inc INHIBITORS OF CATHEPSIN B
UA106748C2 (uk) * 2009-04-20 2014-10-10 Ф. Хоффманн-Ля Рош Аг Похідні проліну як інгібітори катепсину

Also Published As

Publication number Publication date
RU2014123784A (ru) 2015-12-27
US8729061B2 (en) 2014-05-20
EP2782903B1 (en) 2016-04-06
MX2014006211A (es) 2014-08-08
CA2854569A1 (en) 2013-05-30
JP2014533707A (ja) 2014-12-15
KR20140102253A (ko) 2014-08-21
EP2782903A1 (en) 2014-10-01
US20130137687A1 (en) 2013-05-30
WO2013076063A1 (en) 2013-05-30
CN103946213A (zh) 2014-07-23
BR112014012521A2 (pt) 2017-06-06

Similar Documents

Publication Publication Date Title
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR088969A1 (es) Derivados de pirrolidina
AR093805A1 (es) Derivados de piridina agonistas del receptor 2 de cannabinoides
AR093843A1 (es) Derivados de piridina agonistas de receptores cb2
AR094621A1 (es) Compuestos y composiciones farmacéuticas para el tratamiento de infecciones virales
AR088625A1 (es) Derivados de aril-quinolina
AR095721A1 (es) Derivados de piridina
AR096152A1 (es) Derivados de purina
AR094214A1 (es) Inhibidores de la quinasa que regula la señal de la apoptosis
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR090488A1 (es) Derivados de n-ciclobutilbenzamida, un proceso para su obtencion, intermediarios para su sintesis, composiciones pesticidas y farmaceuticas que los comprenden y metodos para controlar daños debidos a una plaga y/u hongos
AR069480A1 (es) Derivados de 2-amino-pirimidina
AR093806A1 (es) Derivados de piridina agonistas de receptores cb2
AR090967A1 (es) Picolinamidas macrociclicas como fungicidas
AR063723A1 (es) 5-oxo-5,8-dihidro-piridopirimidinas inhibidoras de c-fms quinasas, composiciones farmaceuticas que las contienen y usos como agentes anticancer, en enfermedades cardiovasculares y procesos inflamatorios
AR074504A1 (es) Nucleotidos uracil ciclopropilicos
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR099932A1 (es) Derivados de piridina
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR092684A1 (es) Compuestos de sulfonamida sustituidos
AR099853A1 (es) Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
CO6801734A2 (es) Derivados de etinilo como moduladores alostéricos positivos de mglur5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal